Circulation. 2002;106:981-986
Published online before print July 29, 2002, doi: 10.1161/01.CIR.0000027107.54614.1A
Published online before print July 29, 2002, doi: 10.1161/01.CIR.0000027107.54614.1A
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:981.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species
From Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany.
Correspondence to Stefanie Dimmeler, PhD, Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Theodor Stern-Kai 7, 60590 Frankfurt, Germany. E-mail dimmeler{at}em.uni-frankfurt.de
Background— The CD40/CD40 ligand system is involved in atherogenesis. Activated T lymphocytes and platelets, which express high amounts of CD40 ligand (CD40L) on their surface, contribute significantly to plaque instability with ensuing thrombus formation, leading to acute coronary syndromes. Because reendothelialization may play a pivotal role for plaque stabilization, we investigated a potential role of CD40L on endothelial cell (EC) migration.
Methods and Results— Stimulation of ECs with recombinant CD40L prevented vascular endothelial growth factor (VEGF)-induced EC migration, as determined by a "scratched wound assay." In addition, activated T lymphocytes and platelets significantly inhibited VEGF-induced EC migration and tube formation in vitro. Because the activation of endothelial nitric oxide (NO) synthase and the release of NO are required for EC migration and angiogenesis, we analyzed the effect of NO. Coincubation with the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) did not reverse the inhibitory effect of CD40L on VEGF-induced EC migration and tube formation. In addition, EC migration induced by SNAP was completely inhibited by CD40L. CD40L, however, induced the production of reactive oxygen species and reduced endothelial NO bioavailability. This reactive oxygen species-dependent effect of CD40L stimulation was reversed with vitamin C or N-acetylcysteine.
Conclusions— The activation of the CD40 receptor inhibits EC migration by increasing reactive oxygen species. The blockade of EC migration by CD40L may critically affect endothelial regeneration after plaque erosion and thereby may contribute to the increased risk for development of acute coronary events in patients with high circulating levels of CD40L.
Key Words: migration • ligands • endothelium • nitric oxide • reactive oxygen species
This article has been cited by other articles:
 |
|
 |
|
  P. Haddad, S. Dussault, J. Groleau, J. Turgeon, S.-E. Michaud, C. Menard, G. Perez, F. Maingrette, and A. Rivard Nox2-Containing NADPH Oxidase Deficiency Confers Protection From Hindlimb Ischemia in Conditions of Increased Oxidative Stress Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1522 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Stokes, L. Calahan, C. M. Hamric, J. M. Russell, and D. N. Granger CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H689 - H697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. van Gils, J. J. Zwaginga, and P. L. Hordijk Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases J. Leukoc. Biol., February 1, 2009; 85(2): 195 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chen, H. Chai, X. Wang, J. Jiang, M. S. Jamaluddin, D. Liao, Y. Zhang, H. Wang, U. Bharadwaj, S. Zhang, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells Blood, October 15, 2008; 112(8): 3205 - 3216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Li, J. M. Sanders, M. H. Bevard, Z. Sun, J. W. Chumley, E. V. Galkina, K. Ley, and I. J. Sarembock CD40 Ligand Promotes Mac-1 Expression, Leukocyte Recruitment, and Neointima Formation after Vascular Injury Am. J. Pathol., April 1, 2008; 172(4): 1141 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ishizaka, Y. Ishizaka, E.-I. Toda, K. Koike, M. Yamakado, and R. Nagai Are Serum Carcinoembryonic Antigen Levels Associated With Carotid Atherosclerosis in Japanese Men? Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 160 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Davi and C. Patrono Platelet Activation and Atherothrombosis N. Engl. J. Med., December 13, 2007; 357(24): 2482 - 2494. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lefevre, S.-E. Michaud, P. Haddad, S. Dussault, C. Menard, J. Groleau, J. Turgeon, and A. Rivard Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide FASEB J, December 1, 2007; 21(14): 3845 - 3852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chakrabarti, P. Blair, and J. E. Freedman CD40-40L Signaling in Vascular Inflammation J. Biol. Chem., June 22, 2007; 282(25): 18307 - 18317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Prontera, N. Martelli, V. Evangelista, E. D'Urbano, S. Manarini, A. Recchiuti, A. Dragani, C. Passeri, G. Davi, and M. Romano Homocysteine Modulates the CD40/CD40L System J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2182 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Heitzer, V. Rudolph, E. Schwedhelm, M. Karstens, K. Sydow, M. Ortak, P. Tschentscher, T. Meinertz, R. Boger, and S. Baldus Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1648 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weber, B. Rabenau, M. Stanisch, A. Elsaesser, V. Mitrovic, C. Heeschen, and C. Hamm Influence of Sample Type and Storage Conditions on Soluble CD40 Ligand Assessment Clin. Chem., May 1, 2006; 52(5): 888 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Santilli, G. Davi, A. Consoli, F. Cipollone, A. Mezzetti, A. Falco, T. Taraborelli, E. Devangelio, G. Ciabattoni, S. Basili, et al. Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., January 17, 2006; 47(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vorchheimer and R. Becker Platelets in Atherothrombosis Mayo Clin. Proc., January 1, 2006; 81(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chakrabarti, S. Varghese, O. Vitseva, K. Tanriverdi, and J. E. Freedman CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2428 - 2434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Davis and M.-H. Zou CD40 Ligand-Dependent Tyrosine Nitration of Prostacyclin Synthase In Vivo Circulation, October 4, 2005; 112(14): 2184 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Laxmanan, D. Datta, C. Geehan, D. M. Briscoe, and S. Pal CD40: A Mediator of Pro- and Anti-Inflammatory Signals in Renal Tubular Epithelial Cells J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2714 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ishikawa, T. Vowinkel, K. Y. Stokes, T. V. Arumugam, G. Yilmaz, A. Nanda, and D. N. Granger CD40/CD40 Ligand Signaling in Mouse Cerebral Microvasculature After Focal Ischemia/Reperfusion Circulation, April 5, 2005; 111(13): 1690 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sanguigni, D. Ferro, P. Pignatelli, M. Del Ben, T. Nadia, M. Saliola, R. Sorge, and F. Violi CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia J. Am. Coll. Cardiol., January 4, 2005; 45(1): 35 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby, and for the Myocardial Ischemia Reduction with Aggress Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation, July 27, 2004; 110(4): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Furman, L. A. Krueger, M. D. Linden, M. R. Barnard, A. L. Frelinger III, and A. D. Michelson Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Nath, J. Enciso, M. Kuniyasu, X.-Y. Hao, J. A. Madri, and E. Pinter Nitric oxide modulates murine yolk sac vasculogenesis and rescues glucose induced vasculopathy Development, May 15, 2004; 131(10): 2485 - 2496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Granger, T. Vowinkel, and T. Petnehazy Modulation of the Inflammatory Response in Cardiovascular Disease Hypertension, May 1, 2004; 43(5): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, C. Ferri, G. Desideri, L. Paloscia, G. Materazzo, M. Mascellanti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, et al. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty Circulation, December 2, 2003; 108(22): 2776 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Hatoum, H. Miura, and D. G. Binion The vascular contribution in the pathogenesis of inflammatory bowel disease Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1791 - H1796. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Szmitko, C.-H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson, and S. Verma New Markers of Inflammation and Endothelial Cell Activation: Part I Circulation, October 21, 2003; 108(16): 1917 - 1923. [Full Text] [PDF]
|
|
|
|
|
|
T. Heitzer, I. Ollmann, K. Koke, T. Meinertz, and T. Munzel Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease Circulation, August 5, 2003; 108(5): 536 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Desideri, M. C. Bravi, M. Tucci, G. Croce, M. C. Marinucci, A. Santucci, E. Alesse, and C. Ferri Angiotensin II Inhibits Endothelial Cell Motility Through an AT1-Dependent Oxidant-Sensitive Decrement of Nitric Oxide Availability Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1218 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nannizzi-Alaimo, V. L. Alves, and D. R. Phillips Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation Circulation, March 4, 2003; 107(8): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Danese and C. Fiocchi Atherosclerosis and Inflammatory Bowel Disease: Sharing a Common Pathogenic Pathway? Circulation, February 25, 2003; 107 (7): e52 - e52. [Full Text] [PDF]
|
|
|
|
|
|
P. Andre, L. Nannizzi-Alaimo, S. K. Prasad, and D. R. Phillips Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease Circulation, August 20, 2002; 106(8): 896 - 899. [Full Text] [PDF]
|
|